La cadena de opciones muestra datos clave de las opciones de acciones de Aena SME a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aena SME..

Aena SME (OTC:ANYYY) Bolsa, Cadena de Opciones

Aena SME SA is a Spanish airport operator with various airports in Spain, including Madrid and Barcelona, and has stakes in multiple international airports. The group generates regulated and nonregulated revenue. Regulated revenue includes fees collected from takeoff and landing, passenger fees and security, whereas nonregulated revenue stems from commercial activities such as retail, food and beverage and advertising sales. The Group carries out its business activities in the following segments: Airports; Real estate services; Region de Murcia International Airport (AIRM) and International.

ANYYY

CLLNY

ENGGY

IMQCF

MRPRF

RDEIY

¿Cuáles son las empresas del Ibex que han logrado récords de ventas y beneficios en 2024 a pesar de los desafíos económicos? Descúbrelo aquí.

Estas acciones no financieras del Ibex baten récords de beneficios en 2024

Aena SME SA

Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced that it has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-25 (the "Reverse Share Split"). The Reverse Share Split was approved by the Company's shareholders at an annual general meeting of shareholders held on&nbsp;January 10, 2025. The Company's Class A ordinary shares will begin trading on an adjusted basis on the Nasdaq Capital Market, reflecting the Reverse Share Split, when the market opens on&nbsp;January 27, 2025, under the existing ticker symbol "HAO." The new CUSIP number for the Company's Class A ordinary shares will be G4290F118.
Upon the effectiveness of the Reverse Share Split, every twenty-five shares of the Company's issued and outstanding Class A ordinary shares as of the effective date will automatically be combined into one Class A ordinary share, and every twenty-five shares of the Company's issued and outstanding Class B ordinary shares as of the effective date will automatically be combined into one Class B ordinary share. This adjustment will reduce the total number of outstanding Class A ordinary shares of the Company from approximately 53.29 million to approximately 2.13 million, and the total number of outstanding Class B ordinary shares of the Company from approximately 17.27 million to approximately 0.69 million.
In conjunction with the Reverse Share Split, the Company also amended its Articles and Memorandum of Association to proportionately reduce the number of authorized shares for issuance and to adjust the par value of the post-reverse share split ordinary shares to&nbsp;$0.0025&nbsp;per share.
No fractional shares will be issued; instead, shareholders who would otherwise be entitled to a fractional share will have their entitlement rounded up to the nearest whole share.

News

Stock Split

Haoxi Health Technology Limited Announces 1-For-25 Reverse Share Split, Reflecting The Reverse Share Split, When The Market Opens On January 27, 2025

NEGG

Newegg Commerce Announces Listing Of NVIDIA RTX 50 Series GPUs

Earnings

Earnings Beats

OSIS

OSI Systems Q2 2025 Adj. EPS $2.42 Beats $2.33 Estimate, Sales $419.820M Beat $405.990M Estimate

Deutsche Bank analyst Steve Powers maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Hold and lowers the price target from $184 to $148.

Price Target

Analyst Ratings

Deutsche Bank Maintains Hold on Hershey, Lowers Price Target to $148

WIIM

IXHL

Inncannex Healthcare shares are trading lower after the company announced topline results from a completed pharmacokinetics and safety study of IHL-42X for obstructive sleep apnea.

Macro Economic Events

Econ #s

Economics

US Continuing Jobless Claims 1.899M vs 1.86M Est.; Prior 1.853M

In the current market session, Burlington Stores Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) share price is at $289.40, after a 0.17% increase. Moreover, over the past month, the stock decreased by 2.08%, but in the past year, spiked by 45.90%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1737639012_0.png" alt="Past Year Chart" />

<h3>How Does Burlington Stores P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Burlington Stores has a better P/E ratio of 39.74 than the aggregate P/E ratio of 28.07 of the Specialty Retail industry. Ideally, one might believe that Burlington Stores Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1737639012_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

BURL

P/E Ratio Insights for Burlington Stores

Macro Notification

General

US Initial Jobless Claims 223K vs 221K Est.; Prior 217K

Conduit Pharmaceuticals shares are trading lower after the company board approved a 1-for-100 reverse stock split.

B of A Securities analyst Wamsi Mohan maintains TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) with a Buy and raises the price target from $167 to $170.

B of A Securities Maintains Buy on TE Connectivity, Raises Price Target to $170

QNRX

Quoin Pharmaceuticals shares are trading higher after the company announced it advanced its Netherton syndrome treatment and is partnering with Skinvisible to seek FDA-approved topical innovation.

Shares of Li-Metal batteries manufacturer SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) are trading higher in premarket on Thursday.
SES AI has signed contracts valued at up to $10 million with two prominent global OEM partners, marking a milestone in utilizing AI for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43155807/ses-ai-signs-contracts-totaling-up-to-10-million-to-develop-ai-enhanced-li-metal-and-li-ion-batter" rel="noreferrer noopener">discovery of battery materials.</a>
These agreements aim to develop electrolyte materials for Li-Metal and Li-ion batteries in automotive applications.
SES AI said that a portion of the revenue from these contracts will be recognized in the fourth quarter of 2024, with the rest expected to be acknowledged by mid-2025.
These latest agreements with OEM partners build on the company&#8217;s prior announcement of the first battery to use an electrolyte material discovered through its AI-based Molecular Universe project.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43127666/uber-eats-partners-with-home-depot-for-on-demand-deliveries" rel="noreferrer noopener">Uber Eats Partners With Home Depot For On-Demand Deliveries</a>
&#8220;These new contracts with our automotive OEM partners are applying our AI-discovered electrolytes for Li-Metal B-sample developments and for the first time with mature Li-ion batteries already in commercial use,&#8221; said Founder and CEO Qichao Hu.
&#8220;We believe this new revenue stream and these contracts validate and accelerate the commercial use of AI for Science for battery material discovery in automotive applications.&#8221;
Price Action: SES shares are trading higher by 20% at $0.9975 in premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43121964/adidas-sees-solid-gains-in-q4-looks-to-expand-market-share" target="_blank" rel="noreferrer noopener">Adidas Sees Solid Gains In Q4, Looks To Expand Market Share</a></li>
</ul>
Image via Shutterstock.

Equities

Contracts

Movers

SES Secures ~$10M In AI-Powered Battery Contracts; Stock Jumps

Wolfe Research analyst Steve Fleishman downgrades FirstEnergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades FirstEnergy to Peer Perform

B of A Securities analyst Christopher Nardone maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Neutral and raises the price target from $182 to $217.

DECK

B of A Securities Maintains Neutral on Deckers Outdoor, Raises Price Target to $217

Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) disclosed that its Board of Directors has approved a plan to separate its Electrical Distribution Systems (EDS) business from Aptiv, creating two <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43124298/aptiv-unplugs-eds-spin-off-aims-to-supercharge-electrification-automation-and-ai">independent entities</a>.
Aptiv also reaffirmed its 2024 outlook, with a fourth-quarter earnings report scheduled for February 6, 2025. While reporting third-quarter results in October, Aptiv said it expects FY24 adjusted earnings per share in the range of $6.00-$6.30 ($6.12 estimate) and net sales of $19.60 billion-$19.90 billion ($19.68 billion estimate).
Kevin Clark, Aptiv's Chairman and CEO, emphasized that the separation is part of the company's broader transformation strategy.
"Following completion of the transaction, Aptiv will have a portfolio of advanced software and hardware technologies and highly engineered, mission-critical products that are aligned with global mega trends fueling growth in diverse end markets," Clark said.
Aptiv's shares gained 1.5% to close at $62.73 on Wednesday.
These analysts made changes to their price targets on Aptiv following the announcement.
<ul>
<li>Piper Sandler analyst Alexander Potter upgraded Aptiv from Underweight to Neutral and raised the price target from $53 to $65.</li>
<li>Baird analyst David Leiker maintained the stock with a Neutral and raised the price target from $70 to $75.</li>
</ul>
Considering buying APTV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-1024x596.png" alt="" class="wp-image-746807" style="width:503px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23082510/image-175.png 1086w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

APTV

These Analysts Boost Their Forecasts On Aptiv

B of A Securities analyst Wamsi Mohan maintains Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) with a Neutral and raises the price target from $75 to $85.

B of A Securities Maintains Neutral on Amphenol, Raises Price Target to $85

Citigroup analyst Christopher Allen reinstates Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Buy and announces $30 price target.

Initiation

Citigroup Reinstates Buy on Blue Owl Cap, Announces $30 Price Target

B of A Securities analyst Tim Anderson maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and lowers the price target from $160 to $159.

B of A Securities Maintains Neutral on Johnson & Johnson, Lowers Price Target to $159

VIGL

Vigil Neuroscience shares are trading higher after the company reported data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of Alzheimer's disease.

Looking Ahead to 2025
As we enter 2025, we are excited to build on this momentum. Our focus remains on:
<ul>
<li>Identifying key opportunities to advance (Z)-endoxifen into registrational clinical trials with the goal of advancing (Z)-endoxifen to the market in the quickest way possible. This is our company's top priority, and we commit to communicating our progress on this goal in the first quarter of this year.</li>
<li>Amplifying our ongoing business development efforts to ensure women globally have the opportunity to benefit from (Z)-endoxifen.</li>
<li>Deepening collaborations with industry leaders and advocacy groups to broaden the impact of our work.
<ul>
<li>Extending our track record of financial strength that will position us to support our long-term growth.</li>
</ul>
</li>
</ul>

Biotech

ATOS

Atossa Therapeutics Says Z-Endoxifen To Enter Registrational Clinical Trials In 2025; Updates On Progress Expected Q1; Global Business Development Efforts Amplified; Industry Partnerships Deepened; Financial Strength For Long-Term Growth Emphasized

Comments

Aena SME

Aena SME (ANYYY) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL